Portilho A, Trzewikoswki de Lima G, De Gaspari E
Ther Adv Vaccines Immunother. 2020; 8:2515135520919195.
PMID: 32435751
PMC: 7225800.
DOI: 10.1177/2515135520919195.
Colicchio R, Pagliuca C, Pastore G, Cicatiello A, Pagliarulo C, Tala A
Antimicrob Agents Chemother. 2015; 59(12):7637-49.
PMID: 26416867
PMC: 4649176.
DOI: 10.1128/AAC.01746-15.
Pinto V, Burden R, Wagner A, Moran E, Lee C
PLoS One. 2013; 8(11):e79304.
PMID: 24244473
PMC: 3828347.
DOI: 10.1371/journal.pone.0079304.
Lewis L, Ram S
Virulence. 2013; 5(1):98-126.
PMID: 24104403
PMC: 3916388.
DOI: 10.4161/viru.26515.
Hubert K, Pawlik M, Claus H, Jarva H, Meri S, Vogel U
PLoS One. 2012; 7(9):e45132.
PMID: 23028802
PMC: 3447861.
DOI: 10.1371/journal.pone.0045132.
The relative roles of factor H binding protein, neisserial surface protein A, and lipooligosaccharide sialylation in regulation of the alternative pathway of complement on meningococci.
Lewis L, Carter M, Ram S
J Immunol. 2012; 188(10):5063-72.
PMID: 22504643
PMC: 3345070.
DOI: 10.4049/jimmunol.1103748.
Improvement of immunogenicity of meningococcal lipooligosaccharide by coformulation with lipidated transferrin-binding protein B in liposomes: implications for vaccine development.
Mistretta N, Guy B, Berard Y, Dalencon F, Fratantonio O, Gregoire C
Clin Vaccine Immunol. 2012; 19(5):711-22.
PMID: 22441387
PMC: 3346337.
DOI: 10.1128/CVI.05683-11.
Measurement of functional anti-meningococcal serogroup a activity using strain 3125 as the target strain for serum bactericidal assay.
Poolman J, De Vleeschauwer I, Durant N, Devos N, Feron C, Lestrate P
Clin Vaccine Immunol. 2011; 18(7):1108-17.
PMID: 21593240
PMC: 3147334.
DOI: 10.1128/CVI.00549-10.
Human airway epithelial cell responses to Neisseria lactamica and purified porin via Toll-like receptor 2-dependent signaling.
Liu X, Wetzler L, Nascimento L, Massari P
Infect Immun. 2010; 78(12):5314-23.
PMID: 20937766
PMC: 2981301.
DOI: 10.1128/IAI.00681-10.
Infections of people with complement deficiencies and patients who have undergone splenectomy.
Ram S, Lewis L, Rice P
Clin Microbiol Rev. 2010; 23(4):740-80.
PMID: 20930072
PMC: 2952982.
DOI: 10.1128/CMR.00048-09.
The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement.
Lewis L, Ngampasutadol J, Wallace R, Reid J, Vogel U, Ram S
PLoS Pathog. 2010; 6(7):e1001027.
PMID: 20686663
PMC: 2912398.
DOI: 10.1371/journal.ppat.1001027.
Three doses of an experimental detoxified L3-derived lipooligosaccharide meningococcal vaccine offer good safety but low immunogenicity in healthy young adults.
Bonvehi P, Boutriau D, Casellas J, Weynants V, Feron C, Poolman J
Clin Vaccine Immunol. 2010; 17(9):1460-6.
PMID: 20660140
PMC: 2944444.
DOI: 10.1128/CVI.00129-10.
Cellular and molecular biology of Neisseria meningitidis colonization and invasive disease.
Hill D, Griffiths N, Borodina E, Virji M
Clin Sci (Lond). 2010; 118(9):547-64.
PMID: 20132098
PMC: 2830671.
DOI: 10.1042/CS20090513.
Mechanisms in Neisseria meningitidis for resistance against complement-mediated killing.
Kugelberg E, Gollan B, Tang C
Vaccine. 2009; 26 Suppl 8:I34-9.
PMID: 19388162
PMC: 2686086.
DOI: 10.1016/j.vaccine.2008.11.059.
Genetically modified L3,7 and L2 lipooligosaccharides from Neisseria meningitidis serogroup B confer a broad cross-bactericidal response.
Weynants V, Denoel P, Devos N, Janssens D, Feron C, Goraj K
Infect Immun. 2009; 77(5):2084-93.
PMID: 19289516
PMC: 2681751.
DOI: 10.1128/IAI.01108-08.
Modification of lipooligosaccharide with phosphoethanolamine by LptA in Neisseria meningitidis enhances meningococcal adhesion to human endothelial and epithelial cells.
Takahashi H, Carlson R, Muszynski A, Choudhury B, Kim K, Stephens D
Infect Immun. 2008; 76(12):5777-89.
PMID: 18824535
PMC: 2583577.
DOI: 10.1128/IAI.00676-08.
The structure of the L9 immunotype lipooligosaccharide from Neisseria meningitidis NMA Z2491.
Choudhury B, Kahler C, Datta A, Stephens D, Carlson R
Carbohydr Res. 2008; 343(17):2971-9.
PMID: 18804756
PMC: 2784147.
DOI: 10.1016/j.carres.2008.08.026.
Lipooligosaccharide structure contributes to multiple steps in the virulence of Neisseria meningitidis.
Plant L, Sundqvist J, Zughaier S, Lovkvist L, Stephens D, Jonsson A
Infect Immun. 2006; 74(2):1360-7.
PMID: 16428785
PMC: 1360357.
DOI: 10.1128/IAI.74.2.1360-1367.2006.
Biochemical analysis of Lpt3, a protein responsible for phosphoethanolamine addition to lipooligosaccharide of pathogenic Neisseria.
OConnor E, Piekarowicz A, Swanson K, Griffiss J, Stein D
J Bacteriol. 2006; 188(3):1039-48.
PMID: 16428408
PMC: 1347319.
DOI: 10.1128/JB.188.3.1039-1048.2006.
Phase and antigenic variation in bacteria.
van der Woude M, Baumler A
Clin Microbiol Rev. 2004; 17(3):581-611, table of contents.
PMID: 15258095
PMC: 452554.
DOI: 10.1128/CMR.17.3.581-611.2004.